지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2022.1
- 수록면
- 72 - 77 (6page)
- DOI
- 10.5217/ir.2020.00117
이용수
초록· 키워드
오류제보하기
Background/Aims: Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn’s disease (CD). However, even with earlier usage of biologic therapy, a significant proportion of patients will require surgery. Vedolizumab is an anti-integrin antibody that is increasingly used given that it is more gut selective and associated with fewer side effects. The aim of this study is to assess the effect of vedolizumab compared to anti-tumor necrosis factor (anti-TNF) therapy on the perioperative complications in patients undergoing surgery for inflammatory bowel disease (IBD).Methods: Retrospective review of patients treated for IBD at a tertiary care center between 2013 and 2017. Rates of 30- and 90-day complications for patients on vedolizumab were compared to patients on anti-TNF regimens.Results: One hundred and ninety-nine patients met inclusion criteria with 87 (43%) patients undergoing surgery for CD, 111 (55.8%) for UC and 1 (0.5%) for indeterminate colitis. Thirty-eight patients received preoperative vedolizumab and 94 received anti-TNF. There were more males and lower body mass index in the anti-TNF group. There was no significant difference in overall rate of complications at 30 or 90 days. There was a trend for lower leak rate vedolizumab group (0% for vedolizumab vs. 2.1% for anti-TNF at 30 days, P= 1.00; 0% for vedolizumab vs. 1.1% for anti-TNF at 90 days, P= 1.00). Multivariate analysis showed low albumin ( < 3.6 g/dL) at the time of surgery to be a significant risk factor for overall and infectious complications at 90 days (odds ratio, 3.24; 95% confidence interval, 1.12?8.79; P= 0.021).Conclusions: Perioperative vedolizumab does not increase rates of perioperative complications in IBD surgery when compared to anti-TNF medications.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
Intestinal research
2021 .10
-
The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
Journal of Korean Medical Science
2022 .04
-
Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients
Journal of Korean Medical Science
2017 .01
-
Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn’s disease
Intestinal research
2018 .01
-
Current and Emerging Biologics for Ulcerative Colitis
Gut and Liver
2015 .01
-
Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
Gut and Liver
2017 .01
-
Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
Intestinal research
2017 .01
-
Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management
Intestinal research
2018 .01
-
Laparoscopic surgery contributes to a decrease in short-term complications in surgical ulcerative colitis patients during 2008–2017: a multicenter retrospective study in China
Intestinal research
2023 .04
-
Asian Organization for Crohn’s and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
Intestinal research
2018 .01
-
Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
Gut and Liver
2021 .09
-
Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn’s disease
Intestinal research
2022 .07
-
Complications of Spine Surgery in Elderly Japanese Patients: Implications for Future of World Population Aging
Neurospine
2019 .01
-
Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
Intestinal research
2021 .01
-
Impact of anti-tumor necrosis factor treatment on lipid profiles in Korean patients with ankylosing spondylitis
대한류마티스학회지
2024 .01
-
Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study
Yonsei Medical Journal
2020 .01
-
Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn’s disease
Intestinal research
2018 .01
-
Influence of anti-tumor necrosis factor-alpha therapy on pregnant women with inflammatory bowel disease and their children’s immunity
Intestinal research
2019 .01
-
염증장질환의 치료: 생물학적제제 및 새로운 치료법을 중심으로
대한의사협회지
2021 .09
-
염증성 장질환의 약물요법
대한의사협회지
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0